Immune responses to adeno-associated virus and its recombinant vectors (Q35131229)

6 August 2017

1 reference

title

Immune responses to adeno-associated virus and its recombinant vectors (English)

1 reference

6 August 2017

0 references

J Y Sun

1

1 reference

6 August 2017

V Anand-Jawa

series ordinal

2

1 reference

6 August 2017

S Chatterjee

series ordinal

3

1 reference

6 August 2017

K K Wong

series ordinal

4

1 reference

6 August 2017

1 June 2003

1 reference

6 August 2017

1 reference

6 August 2017

10

1 reference

6 August 2017

964-976

1 reference

6 August 2017

11

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.gt.3302039

6 August 2017

0 references

cites work

Hot topics in adeno-associated virus as a gene transfer vector

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Immunogenic issues concerning recombinant adeno-associated virus vectors for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Ubiquitous human adeno-associated virus type 2 autonomously replicates in differentiating keratinocytes of a normal skin model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Site-specific integration by adeno-associated virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Quantitative analysis of the packaging capacity of recombinant adeno-associated virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Immune responses to adenovirus and adeno-associated virus in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

A deviant immune response to viral proteins and transgene product is generated on subretinal administration of adenovirus and adeno-associated virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

A seroepidemiologic study of adenovirus-associated virus infection in infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

The tumor suppressive properties of adeno-associated viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Gene therapy: recombinant adeno-associated virus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Additional transduction events after subretinal readministration of recombinant adeno-associated virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Recombinant adeno-associated virus for muscle directed gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Efficient coexpression and secretion of anti-atherogenic human apolipoprotein AI and lecithin-cholesterol acyltransferase by cultured muscle cells using adeno-associated virus plasmid vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Expression of the human multidrug resistance and glucocerebrosidase cDNAs from adeno-associated vectors: efficient promoter activity of AAV sequences and in vivo delivery via liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Efficient gene transfer into human cord blood CD34+ cells and the CD34+CD38- subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Adeno-associated virus 2-mediated transduction and erythroid lineage-restricted long-term expression of the human beta-globin gene in hematopoietic cells from homozygous beta-thalassemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

A high-capacity, capsid-modified hybrid adenovirus/adeno-associated virus vector for stable transduction of human hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Factors influencing cross-presentation of non-self antigens expressed from recombinant adeno-associated virus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Induction of tolerance to human factor VIII in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

In utero gene therapy: the case against

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Sustained delivery of therapeutic concentrations of human clotting factor IX--a comparison of adenoviral and AAV vectors administered in utero

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

In utero delivery of adeno-associated viral vectors: intraperitoneal gene transfer produces long-term expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Humoral immune response to recombinant adenovirus and adeno-associated virus after in utero administration of viral vectors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Virus-mediated killing of cells that lack p53 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

7 January 2021

Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

7 January 2021

Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

7 January 2021

Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

7 January 2021

The immune response and the eye. TCR alpha-chain related molecules regulate the systemic immunity to antigen presented in the eye

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

7 January 2021

Infection of primary cells by adeno-associated virus type 2 results in a modulation of cell cycle-regulating proteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

7 January 2021

Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

7 January 2021

Discrimination between different types of human adeno-associated viruses in clinical samples by PCR

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

7 January 2021

Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

7 January 2021

Homing efficiency, cell cycle kinetics, and survival of quiescent and cycling human CD34(+) cells transplanted into conditioned NOD/SCID recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

7 January 2021

Adeno-associated virus type 2-mediated transduction in primary human bone marrow-derived CD34+ hematopoietic progenitor cells: donor variation and correlation of transgene expression with cellular differentiation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

7 January 2021

Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

7 January 2021

Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

7 January 2021

An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

7 January 2021

Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302039

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3302039

1 reference

6 August 2017

1 reference